Suppr超能文献

接受透析患者的肠道微生物群:综述

Gut Microbiota in Patients Receiving Dialysis: A Review.

作者信息

Lim Xintian, Ooi Lijin, Ding Uzhe, Wu Henry H L, Chinnadurai Rajkumar

机构信息

Department of Renal Medicine, Northern Care Alliance NHS Foundation Trust, Salford M6 8HD, UK.

Renal Research Laboratory, Kolling Institute of Medical Research, Royal North Shore Hospital, The University of Sydney, Sydney, NSW 2065, Australia.

出版信息

Pathogens. 2024 Sep 15;13(9):801. doi: 10.3390/pathogens13090801.

Abstract

The human gut microbiota constitutes a complex community of microorganisms residing within the gastrointestinal tract, encompassing a vast array of species that play crucial roles in health and disease. The disease processes involved in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are now increasingly established to result in dysregulation of gut microbiota composition and function. Gut microbiota dysbiosis has been associated with poor clinical outcomes and all-cause mortality in patients with ESKD, particularly individuals receiving dialysis. Prior studies highlighted various factors that affect gut microbiota dysbiosis in CKD and ESKD. These include, but are not limited to, uraemic toxin accumulation, chronic inflammation, immune dysfunction, medications, and dietary restrictions and nutritional status. There is a lack of studies at present that focus on the evaluation of gut microbiota dysbiosis in the context of dialysis. Knowledge on gut microbiota changes in this context is important for determining their impact on dialysis-specific and overall outcomes for this patient cohort. More importantly, evaluating gut microbiota composition can provide information into potential targets for therapeutic intervention. Identification of specific microbial signatures may result in further development of personalised treatments to improve patient outcomes and mitigate complications during dialysis. Optimising gut microbiota through various therapeutic approaches, including dietary adjustments, probiotics, prebiotics, medications, and faecal transplantation, have previously demonstrated potential in multiple medical conditions. It remains to be seen whether these therapeutic approaches are effective within the dialysis setting. Our review aims to evaluate evidence relating to alterations in the gut microbiota of patients undergoing dialysis. A growing body of evidence pointing to the complex yet significant relationship which surrounds gut microbiota and kidney health emphasises the importance of gut microbial balance to improve outcomes for individuals receiving dialysis.

摘要

人类肠道微生物群构成了一个存在于胃肠道内的复杂微生物群落,包含种类繁多的物种,这些物种在健康和疾病中发挥着关键作用。现在越来越多地证实,慢性肾脏病(CKD)和终末期肾病(ESKD)所涉及的疾病过程会导致肠道微生物群组成和功能失调。肠道微生物群失调与ESKD患者,尤其是接受透析的患者的不良临床结局和全因死亡率相关。先前的研究强调了影响CKD和ESKD患者肠道微生物群失调的各种因素。这些因素包括但不限于尿毒症毒素积累、慢性炎症、免疫功能障碍、药物、饮食限制和营养状况。目前缺乏在透析背景下评估肠道微生物群失调的研究。了解这一背景下肠道微生物群的变化对于确定它们对该患者群体的透析特异性和总体结局的影响很重要。更重要的是,评估肠道微生物群组成可以为治疗干预的潜在靶点提供信息。识别特定的微生物特征可能会进一步推动个性化治疗的发展,以改善患者结局并减轻透析期间的并发症。通过各种治疗方法优化肠道微生物群,包括饮食调整、益生菌、益生元、药物和粪便移植,此前已在多种医疗状况中显示出潜力。这些治疗方法在透析环境中是否有效还有待观察。我们的综述旨在评估与透析患者肠道微生物群改变相关的证据。越来越多的证据表明肠道微生物群与肾脏健康之间存在复杂而重要的关系,这强调了肠道微生物平衡对于改善透析患者结局的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c20/11434973/5da3d9581d1c/pathogens-13-00801-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验